EGFR and lung adenocarcinoma: Zhang et al. [30] conducted a retrospective single-center study of 248 patients with lung adenocarcinoma (135 men and 113 women, mean age of 62.43 ± 9.19 years) and investigated the prediction capacity of pretherapy 18F-FDG PET/CT-based radiomics features for EGFR mutation status in patients with NSCLC.